VTYX20251219P2.5
VTYX Dec 19 2025 2.50 Put (VTYX251219P00002500)
option OPRA

we are a biotechnology company with a diverse portfolio of best-in-class highly differentiated clinical and pre-clinical stage programs focused on high value targets. ventyx now includes combined assets from three separate companies: oppilan pharma, targeting s1p1r, zomagen biosciences, targeting nlrp3 and the inflammasome, and ventyx biosciences, targeting tyk2.